bt5528
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2019 (NCT04180371)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Ephrin type-A receptor 2INHIBITOR
EPHA2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04180371 | Phase 1/Phase 2 (Phase 2) | Nov 7, 2019 | Bicycle Therapeutics, Tennessee Oncology, PLLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bicycle Therapeutics | For profit | 1 | 1 | 1 | 2019 |
| Tennessee Oncology, PLLC | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1